IMCR on Nasdaq

Immunocore Holdings plc

We are a commercial stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases, and.3 From its latest annual report

Price unavailable

Last updated Oct 19, 2026.

Overview

Compare with Krystal Biotech, Inc., Twist Bioscience or Tarsus Pharmaceuticals, Inc., or pick any stock.

  • TickerIMCR on Nasdaq1
  • IndustryBiological Products, (No Diagnostic Substances)1
  • HeadquartersOxfordshire, United Kingdom1
  • Incorporated inUnited Kingdom2
  • Business address90 Park Drive, Milton Park, Abingdon, Oxfordshire, X0 Ox14 4Ry2
  • Filer categoryLarge accelerated filer2
  • Legal formCorporation

See how the biggest companies compare on our leaderboards

We are a commercial stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases, and autoimmune diseases. Leveraging our proprietary, flexible, off-the-shelf ImmTAX ® ( I mmune m obilizing m onoclonal T CRs A gainst X disease) platform, we are developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, advanced pre-clinical programs in autoimmune disease and earlier pre-clinical programs across three therapeutic areas.3 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

-11.3%Operating margin4
-8.9%Net margin4
29.0%Revenue growth, 20254
-9.3%Return on equity4
-$15.1MFree cash flow4

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Cost of revenue1¢$5.1M
  • Research and development60¢$274.9M
  • Selling, general and admin36¢$165.4M
  • Income tax4¢$16.4M

Out of $400.0M in revenue.4 The company lost money this year.

Financial statements

Revenue56784$400.0M in 2025+1458% since 2019
0$200.0M$400.0M$600.0M2019: $25.7M$25.7M20192020: $30.1M$30.1M2020+17%2021: $4.1M$4.1M2021−86%2022: $174.4M$174.4M2022+4176%2023: $249.4M$249.4M2023+43%2024: $310.2M$310.2M2024+24%2025: $400.0M$400.0M2025+29%
Operating income56784-$45.4M in 2025−62% since 2019
-$200.0M-$150.0M-$100.0M-$50.0M02019: -$118.3M-$118.3M20192020: -$86.2M-$86.2M2020−27%2021: -$174.6M-$174.6M2021+103%2022: -$51.7M-$51.7M2022−70%2023: -$59.6M-$59.6M2023+15%2024: -$70.5M-$70.5M2024+18%2025: -$45.4M-$45.4M2025−36%
Net income56784-$35.5M in 2025−66% since 2019
-$200.0M-$150.0M-$100.0M-$50.0M02019: -$103.9M-$103.9M20192020: -$74.1M-$74.1M2020−29%2021: -$180.0M-$180.0M2021+143%2022: -$52.5M-$52.5M2022−71%2023: -$55.3M-$55.3M2023+5%2024: -$51.1M-$51.1M2024−8%2025: -$35.5M-$35.5M2025−30%

Every line of the income statement as filed: the last 3 fiscal years, latest first.4

Period ending2025-12-312024-12-312023-12-31
Total revenue$400.0M$310.2M$249.4M
Cost of revenue from sale of therapies-$5.1M-$2.7M-$1.0M
Research and development expense-$274.9M-$222.2M-$163.5M
Selling, general and administrative expense-$165.4M-$155.8M-$144.5M
Loss from operations-$45.4M-$70.5M-$59.6M
Interest income$16.5M$25.6M$18.0M
Interest expense-$12.2M-$18.8M-$5.2M
Foreign currency gain (loss)$2.2M-$3.4M-$13.2M
Other income (expense), net$19.7M$14.2M-$897.0K
Net loss before income taxes-$19.1M-$52.9M-$60.9M
Income tax (expense) benefit-$16.4M$1.9M$5.6M
Net loss-$35.5M-$51.1M-$55.3M
Exchange differences on translation of foreign operations$5.7M$2.5M$18.4M
Total comprehensive loss-$29.8M-$48.6M-$36.9M
Basic net loss per share (in dollars per share)-$0.71-$1.02-$1.13
Diluted net loss per share (in dollars per share)-$0.71-$1.02-$1.13
Basic weighted-average number of shares outstanding (in shares)50.3M shares50.0M shares48.9M shares
Diluted weighted-average number of shares outstanding (in shares)50.3M shares50.0M shares48.9M shares

Compare Immunocore Holdings plc with another company

Leadership

Who has led Immunocore Holdings plc, and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Bahija Jallal2024–now

Chief financial officer

  1. Donato Brian Di2024
  2. Travis Alan Coy2025–now
2025
Board members and other officers (15)

Named in SEC Form D filings

People the company listed in its private-offering notices.

  • Chief Financial OfficerBrian Di Donato named Jul 28, 202227
  • Head of Research and DevelopmentDavid Berman named Jul 28, 202227
  • Chief Human Resources OfficerTina St. Leger named Jul 28, 202227

Former names

  • Immunocore LtdApr 13, 2016 to Feb 1, 20212

Timeline

  1. Jan 2, 2024New chief executive Bahija Jallal becomes CEO12

Filings

243 filings to the SEC since October 2021: 5 annual reports, 8 quarterly reports, 33 major events, 61 insider forms, 48 large holders, 1 private raises, 87 other. The latest 20:

  1. Oct 7, 2026SCHEDULE 13G/A EDGAR
  2. Sep 14, 20268-K EDGAR
  3. Aug 14, 2026SCHEDULE 13G/A EDGAR
  4. Aug 13, 2026SCHEDULE 13G/A EDGAR
  5. Aug 6, 202610-Q EDGAR
  6. Aug 6, 20268-K EDGAR
  7. Aug 6, 2026SCHEDULE 13G/A EDGAR
  8. May 28, 20264 EDGAR
  9. May 28, 20264 EDGAR
  10. May 28, 20264 EDGAR
  11. May 28, 20264 EDGAR
  12. May 28, 20264 EDGAR
  13. May 28, 20264 EDGAR
  14. May 27, 20268-K EDGAR
  15. May 22, 2026144 EDGAR
  16. May 21, 2026144 EDGAR
  17. May 15, 2026SCHEDULE 13G/A EDGAR
  18. May 15, 2026SCHEDULE 13G EDGAR
  19. May 8, 2026S-8 EDGAR
  20. May 6, 202610-Q EDGAR

The 243 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

21 open-market trades by officers, directors and large owners since October 2021: 1 buys and 20 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Feb 18, 2026St Leger Tina AmberCHIEF HR OFFICERSale1,000$32.35$32.4KForm 4
Feb 18, 2026Berman David MHEAD OF R&DSale5,965$32.35$193.0KForm 4
Feb 18, 2026GOLL JOHNSVP, FINANCE & CAOSale698$32.35$22.6KForm 4
Feb 18, 2026Jallal BahijaCHIEF EXECUTIVE OFFICERSale11,474$32.35$371.2KForm 4
Dec 5, 2025Berman David MHEAD OF R&DSale572$40.14$23.0KForm 4
Dec 4, 2025Berman David MHEAD OF R&DSale31,341$40.26$1.3MForm 4
Nov 28, 2025Berman David MHEAD OF R&DSale5,521$40.09$221.3KForm 4
Nov 26, 2025Berman David MHEAD OF R&DSale69,404$40.12$2.8MForm 4
Nov 25, 2025Berman David MHEAD OF R&DSale18,020$40.03$721.3KForm 4
Nov 24, 2025Berman David MHEAD OF R&DSale100$40.00$4.0KForm 4
Sep 30, 2025Berman David MHEAD OF R&DSale61,849$35.23$2.2MForm 4
Sep 15, 2025Berman David MHEAD OF R&DSale200$35.01$7.0KForm 4
Sep 12, 2025Berman David MHEAD OF R&DSale22,532$35.67$803.7KForm 4
Sep 11, 2025Berman David MHEAD OF R&DSale19,081$36.28$692.3KForm 4
Sep 10, 2025Berman David MHEAD OF R&DSale31,338$36.14$1.1MForm 4
Mar 17, 2025667, L.P.DirectorBuy807,338$29.72$24.0MForm 4
Apr 1, 2024St Leger Tina AmberCHIEF HR OFFICERSale4,375$64.06$280.3KForm 4
Feb 28, 2024Berman David MHEAD OF R&DSale36,509$68.59$2.5MForm 4
Feb 27, 2024Berman David MHEAD OF R&DSale54,938$70.86$3.9MForm 4
Feb 26, 2024Berman David MHEAD OF R&DSale28,553$70.65$2.0MForm 4

All 21 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Money raised

Private offerings the company reported to the SEC on Form D.

  1. Jul 20, 2022Raised $140 million in a private offering of equity Form D: 8 investors so far Form D

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Wellington Management Group Llp5,721,945$181.7M0.0%+1,015,777
Rtw Investments, LP4,869,798$154.6M1.3%No change
Fmr LLC4,307,246$136.8M0.0%−521,908
Primecap Management Co/ca/3,638,241$115.5M0.1%−55,000
Bellevue Group AG2,788,245$88.5M1.9%−8,558
Tang Capital Management LLC2,649,368$84.1M3.8%No change
Vestal Point Capital, LP1,800,000$57.1M1.3%−966,868
Two Sigma Investments, LP1,648,983$52.4M0.0%+627,718
Millennium Management LLC1,597,037$50.7M0.0%+359,634
Armistice Capital, LLC1,428,000$45.3M1.3%+240,000
Caligan Partners LP1,381,317$43.9M2.1%New
Kynam Capital Management, LP1,375,000$43.7M2.4%+490,063
Bvf Inc/il1,294,463$41.1M1.1%No change
Trails Edge Capital Partners, LP1,063,234$33.8M5.4%+380,637
BlackRock, Inc.1,004,598$31.9M0.0%+348,289
Point72 Asset Management, L.P.990,280$31.4M0.0%−111,991
Jupiter Topco LLC709,022$22.5M0.0%New
Cantor Fitzgerald, L. P.680,200$21.6M0.2%+429,989
Logos Global Management LP600,000$19.1M0.8%−900,000
Marshall Wace, Llp590,941$18.8M0.0%+410,601
Hudson Bay Capital Management LP590,000$18.7M0.1%−43,174
Citadel Advisors LLC566,761$18.0M0.0%+336,362
Braidwell LP521,327$16.6M0.6%New
Jones Hill Capital LP512,856$16.3M3.5%New
Principal Financial Group Inc485,789$15.4M0.0%−33,341

13F reports cover disclosed long positions in U.S. stocks only.

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44